To include your compound in the COVID-19 Resource Center, submit it here.

Etomoxir: Phase II results

MDG discontinued development of Etomoxir to treat CHF after the product did

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE